本帖最后由 老马 于 2013-3-13 13:43 编辑 ( h/ _# M$ [+ X& c; b+ h |
$ Y$ L: t8 K3 s
健择(吉西他滨)+顺铂+阿瓦斯汀
5 d# f' K' }1 S$ @$ N, ^ Gemzar +Cisplatin + Avastin/ ]/ r- C" W4 Y6 N9 h' C7 H
http://annonc.oxfordjournals.org/content/21/9/1804.full/ K: _" Z0 X, W* P* W
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 O7 F# `( X+ T- Z0 c7 R
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; ~2 p, e+ z; }7 K! k/ OResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
$ z7 Y) a3 O7 c3 ^3 [/ P
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 919)
1 i! y' P4 A! J6 {) w2 K- k i华为网盘附件:
2 J& j r8 v z+ \【华为网盘】ava.JPG5 e2 n0 U: u3 D
|